MedTrace Logo

Rituximab and ABVD for Hodgkin's Patients

NCT00504504 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2013-07-09

Study results available
· View outcomes & findings →

Summary

Primary Objective:

\- To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy.

ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.

Conditions

Interventions

DRUG

Rituximab

375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.

DRUG

Adriamycin

25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

DRUG

Bleomycin

10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

DRUG

Vinblastine

6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

DRUG

Dacarbazine (DTIC)

375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Anas Younes, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504504 on ClinicalTrials.gov